In this episode of the Midweek Takeaway, we’re joined by James Short, CEO of Celadon Pharmaceuticals, to discuss the company’s recent £1 million funding, its decision to delist from AIM, and what that means for its future. We also explore major operational milestones, including progress on EU exports, a Q3 UK product launch, US market entry, expanded growing capacity, and the completion of multiple harvests.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.